Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

Evaluate safety, tolerability, and efficacy of various doses of STP705 administered as intralesional injection in subjects with facial isSCC. There will be 3 cohorts of 10 subjects each. Enrolled subjects will receive STP705 once weekly for 6 weeks. The lesion will be excised 60 days after.